Moderna Expects Total Revenue Growth Of 15% To 25% In 2026
Nov 6 (Reuters) - Moderna, Inc. MRNA.O:
MODERNA Q3 EPS $0.38 VERSUS IBES ESTIMATE $-1.25
MODERNA Q3 REVENUE $1.31 BILLION VERSUS IBES ESTIMATE $885.1 MILLION
MODERNA: CAPITAL EXPENDITURES FOR 2026 EXPECTED TO BE ABOUT $0.2 BILLION
MODERNA FY2026 REVENUE VIEW $2.10 BILLION -- LSEG IBES DATA
MODERNA: RESEARCH & DEVELOPMENT EXPENSES FOR 2026 EXPECTED TO BE ABOUT $2.7 BILLION
MODERNA: DOES NOT PLAN TO INITIATE AN ADDITIONAL COHORT THIS SEASON FOR NOROVIRUS VACCINE
MODERNA: COST OF SALES FOR 2026 EXPECTED TO BE ABOUT $1.7 BILLION
MODERNA: CONDUCTING LIMITED US LAUNCH OF SEASONAL INFLUENZA VACCINE FOR 2026–2027 INFLUENZA SEASON, WITH APPROVAL AFTER ANNUAL CONTRACTING CYCLE
MODERNA: EXPECTS TOTAL REVENUE GROWTH OF 15% TO 25% IN 2026
Further company coverage: MRNA.O